The complaint, filed by the Law Offices of Howard G. Smith, covers the period between February 10, 2025, and May 14, 2026. It asserts that Aardvark Therapeutics executives provided materially false information to the market, concealing critical adverse facts about the company's core operations. Specifically, the suit alleges that the firm overstated the safety profile of ARD-101, which in turn inflated expectations regarding the drug's clinical and regulatory prospects. Investors seeking to discuss their legal rights or participate in the action may reach the firm at (215) 638-4847 or via their website. Those who purchased shares during the specified timeframe are automatically considered class members, meaning they are not required to take immediate action to remain part of the suit.